Prognostic Factors for Patients with Bone-only Metastasis in Breast Cancer

Overview

Journal Yonsei Med J

Specialty General Medicine

Date 2013 Aug 7

PMID 23918566

Citations 55

Authors

Sung Gwe Ahn

Hak Min Lee

Sang-Hoon Cho

Seung Ah Lee

Seung Hyun Hwang

Joon Jeong

Hy-De Lee

Affiliations

Soon will be listed here.

Abstract

Purpose: Bone is the most frequent site of metastasis among breast cancer patients. We investigated prognostic factors affecting survival following bone-only metastasis in breast cancer patients.

Materials And Methods: The medical records of breast cancer patients who were treated and followed at Gangnam Severance Hospital retrospectively reviewed to identify patients with bone-only metastasis.

Results: The median time from the diagnosis of bone-only metastasis to the last follow-up or death was 55.2 [95% confidence interval (CI), 38.6-71.9] months. The Kaplan-Meier overall survival estimate at 10 years for all patients was 34.9%. In the multivariate Cox regression model, bisphosphonate treatment [hazard ratio=0.18; 95% CI, 0.07-0.43], estrogen receptor positivity (hazard ratio=0.51; 95% CI, 0.28-0.94), and solitary bone metastasis (hazard ratio=0.32; 95% CI, 0.14-0.72) were significantly associated with longer overall survival in the bone-only recurrence group. Among the treatment modalities, only bisphosphonate treatment was identified as a significant prognostic factor.

Conclusion: Identifying the factors influencing breast cancer mortality after bone-only metastasis will help clarify the clinical course and improve the treatment outcome for patients with breast cancer and bone-only metastasis. Bisphosphonates, as a significant prognostic factor, warrant further investigation.

Citing Articles

A Comparison of the Efficacy and Safety of Denosumab and Zoledronic Acid in Patients with Bone Metastatic Breast Cancer Receiving CDK4/6 Inhibitor Therapy.

Oner I, Anik H, Kurt Inci B, Kubilay Tolunay P, Ates O, Yalcintas Arslan U Medicina (Kaunas). 2025; 61(2).

PMID: 40005476 PMC: 11857531. DOI: 10.3390/medicina61020360.

Factors Associating with Bone-Only Metastasis in Chinese Breast Cancer Patients in the Absence of Anti-Human Epidermal Growth Factor Receptor 2-Targeted Therapy.

Li Z, Chen L, Han H, Shang Y, Li Y, Jia Z Oncol Res Treat. 2024; 48(3):112-124.

PMID: 39681104 PMC: 11878413. DOI: 10.1159/000543137.

Concise review: breast cancer stems cells and their role in metastases.

Farahani M, Farjadmehr M, Atashi A, Momeni A, Behzadifard M Ann Med Surg (Lond). 2024; 86(9):5266-5275.

PMID: 39238997 PMC: 11374310. DOI: 10.1097/MS9.0000000000002270.

Do metastatic volumes measured in breast cancer patients with bone metastases correlate with the numbers of skeletal and extraskeletal events?.

Yagar H, Aytekin M, Dede D, Sendur M, Ozturk R, Yalcin B Jt Dis Relat Surg. 2023; 35(1):105-111.

PMID: 38108171 PMC: 10746892. DOI: 10.52312/jdrs.2023.1333.

A Web-based Prediction Model for Early Death in Patients With Metastatic Triple-negative Breast Cancer.

Pan W, Ren S, Zhu L, Lin B Am J Clin Oncol. 2023; 47(2):71-80.

PMID: 37871164 PMC: 10805354. DOI: 10.1097/COC.0000000000001058.

References

Koizumi M, Yoshimoto M, Kasumi F, Ogata E . Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients. Ann Oncol. 2003; 14(8):1234-40. DOI: 10.1093/annonc/mdg348. View

Fredriksson I, Liljegren G, Arnesson L, Emdin S, Palm-Sjovall M, Fornander T . Local recurrence in the breast after conservative surgery--a study of prognosis and prognostic factors in 391 women. Eur J Cancer. 2002; 38(14):1860-70. DOI: 10.1016/s0959-8049(02)00219-8. View

Plunkett T, Smith P, Rubens R . Risk of complications from bone metastases in breast cancer. implications for management. Eur J Cancer. 2000; 36(4):476-82. DOI: 10.1016/s0959-8049(99)00331-7. View

Rosen L, Gordon D, Kaminski M, Howell A, Belch A, Mackey J . Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003; 98(8):1735-44. DOI: 10.1002/cncr.11701. View

Rosen L, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M . Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003; 21(16):3150-7. DOI: 10.1200/JCO.2003.04.105. View

Jagdev S, Coleman R, Shipman C, Croucher P . The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001; 84(8):1126-34. PMC: 2363858. DOI: 10.1054/bjoc.2001.1727. View

Yan T, Yin W, Zhou Q, Zhou L, Jiang Y, Du Y . The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer. 2011; 48(2):187-95. DOI: 10.1016/j.ejca.2011.10.021. View

Neville-Webbe H, Evans C, Coleman R, Holen I . Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol. 2006; 27(2):92-103. DOI: 10.1159/000092489. View

Hortobagyi G, Theriault R, Lipton A, Porter L, Blayney D, Sinoff C . Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998; 16(6):2038-44. DOI: 10.1200/JCO.1998.16.6.2038. View

10.

Hortobagyi G . Treatment of breast cancer. N Engl J Med. 1998; 339(14):974-84. DOI: 10.1056/NEJM199810013391407. View

11.

Niikura N, Liu J, Hayashi N, Palla S, Tokuda Y, Hortobagyi G . Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis. Oncologist. 2011; 16(2):155-64. PMC: 3228079. DOI: 10.1634/theoncologist.2010-0350. View

12.

Ottewell P, Monkkonen H, Jones M, Lefley D, Coleman R, Holen I . Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst. 2008; 100(16):1167-78. DOI: 10.1093/jnci/djn240. View

13.

Goldhirsch A, Gelber R, Castiglione M . Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. J Clin Oncol. 1988; 6(1):89-97. DOI: 10.1200/JCO.1988.6.1.89. View

14.

Lipton A, Theriault R, Hortobagyi G, Simeone J, Knight R, Mellars K . Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000; 88(5):1082-90. DOI: 10.1002/(sici)1097-0142(20000301)88:5<1082::aid-cncr20>3.0.co;2-z. View

15.

Clark G, Sledge Jr G, Osborne C, McGuire W . Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol. 1987; 5(1):55-61. DOI: 10.1200/JCO.1987.5.1.55. View

16.

Park I, Ro J, Nam B, Kwon Y, Lee K . Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases. BMC Cancer. 2009; 9:154. PMC: 2694816. DOI: 10.1186/1471-2407-9-154. View

17.

Coleman R, Smith P, Rubens R . Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer. 1998; 77(2):336-40. PMC: 2151240. DOI: 10.1038/bjc.1998.52. View

18.

Scheid V, Buzdar A, Smith T, Hortobagyi G . Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer. 1986; 58(12):2589-93. DOI: 10.1002/1097-0142(19861215)58:12<2589::aid-cncr2820581206>3.0.co;2-o. View

19.

Howell A, Barnes D, Harland R, Redford J, Bramwell V, Wilkinson M . Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet. 1984; 1(8377):588-91. DOI: 10.1016/s0140-6736(84)90995-4. View

20.

Domchek S, Younger J, Finkelstein D, Seiden M . Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer. 2000; 89(2):363-8. DOI: 10.1002/1097-0142(20000715)89:2<363::aid-cncr22>3.0.co;2-3. View